Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comte Hospital, France

Affiliation auteurs!!!! Error affiliation !!!!
TitrePost-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comte Hospital, France
Type de publicationJournal Article
Year of Publication2021
AuteursZayet S, Zahra H, Royer P-Y, Tipirdamaz C, Mercier J, Gendrin V, Lepiller Q, Marty-Quinternet S, Osman M, Belfeki N, Toko L, Garnier P, Pierron A, Plantin J, Messin L, Villemain M, Bouiller K, Klopfenstein T
JournalMICROORGANISMS
Volume9
Pagination1719
Date PublishedAUG
Type of ArticleArticle
Mots-clésDyspnea, Fatigue, Follow-up, Health care workers, long COVID-19, post-COVID-19
Résumé

{(1) Background. Post-COVID-19 syndrome is defined as the persistence of symptoms after confirmed SARS-CoV-2 infection. (2) Methods. ANOSVID is an observational retrospective study in Nord Franche-Comte Hospital in France that included adult COVID-19 patients confirmed by RT-PCR from 1 March 2020 to 31 May 2020. The aim was to describe patients with post-COVID-19 syndrome with persistent symptoms (PS group) and to compare them with the patients without persistent symptoms (no-PS group). (3) Results. Of the 354 COVID-19 patients, 35.9% (n = 127) reported persistence of at least one symptom after a mean of 289.1 +/- 24.5 days after symptom onset. Moreover, 115 patients reported a recurrence of symptoms after recovery, and only 12 patients reported continuous symptoms. The mean age of patients was 48.6 years (19-93) +/- 19.4, and 81 patients (63.8%) were female. Patients in the PS group had a longer duration of symptoms of initial acute SARS-CoV-2 infection than patients in the no-PS group (respectively, 57.1 +/- 82.1 days versus 29.7 +/- 42.1 days, p < 0.001). A majority of patients (n = 104, 81.9%) reported three or more symptoms. The most prevalent persistent symptoms were loss of smell (74.0%

DOI10.3390/microorganisms9081719